MedTrace Logo

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2012-02-27

Study results available
· View outcomes & findings →

Summary

We will evaluate the efficacy of PN400 and an active comparator in patients that have Osteoarthritis of the knee.

Conditions

Interventions

DRUG

PN 400 (VIMOVO)

500 mg naproxen/20 mg esomeprazole bid

DRUG

celebrex

200 mg celecoxib qd

DRUG

Placebo

sugar pill bid

DRUG

Rescue Antacid

Antacid Tablets

Sponsors & Collaborators

  • POZEN

    lead INDUSTRY

Principal Investigators

  • Everardus Orlemans, PhD · POZEN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664560 on ClinicalTrials.gov